MX2024001276A - Esquema de dosificacion de agonistas de los receptores de glp1/glucagon de accion prolongada. - Google Patents

Esquema de dosificacion de agonistas de los receptores de glp1/glucagon de accion prolongada.

Info

Publication number
MX2024001276A
MX2024001276A MX2024001276A MX2024001276A MX2024001276A MX 2024001276 A MX2024001276 A MX 2024001276A MX 2024001276 A MX2024001276 A MX 2024001276A MX 2024001276 A MX2024001276 A MX 2024001276A MX 2024001276 A MX2024001276 A MX 2024001276A
Authority
MX
Mexico
Prior art keywords
long
receptor agonists
glucagon receptor
dose regimen
glp1
Prior art date
Application number
MX2024001276A
Other languages
English (en)
Spanish (es)
Inventor
Michael Desch
Anita Magdalena Hennige
Corinna Isabel Schoelch
Claus Thamer
Jan Per Martin Bergstrand
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2024001276A publication Critical patent/MX2024001276A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024001276A 2021-07-30 2022-07-28 Esquema de dosificacion de agonistas de los receptores de glp1/glucagon de accion prolongada. MX2024001276A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21188741 2021-07-30
PCT/EP2022/071281 WO2023006923A1 (en) 2021-07-30 2022-07-28 Dose regimen for long-acting glp1/glucagon receptor agonists

Publications (1)

Publication Number Publication Date
MX2024001276A true MX2024001276A (es) 2024-02-15

Family

ID=77155646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001276A MX2024001276A (es) 2021-07-30 2022-07-28 Esquema de dosificacion de agonistas de los receptores de glp1/glucagon de accion prolongada.

Country Status (10)

Country Link
US (1) US20250262279A1 (https=)
EP (1) EP4376871A1 (https=)
JP (1) JP2024529452A (https=)
KR (1) KR20240043778A (https=)
CN (1) CN117677395A (https=)
AU (1) AU2022320922A1 (https=)
CA (1) CA3226846A1 (https=)
CL (1) CL2024000222A1 (https=)
MX (1) MX2024001276A (https=)
WO (1) WO2023006923A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US10336802B2 (en) * 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR107890A1 (es) 2016-03-10 2018-06-28 Medimmune Ltd Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AU2018314773A1 (en) * 2017-08-09 2020-03-26 Sanofi GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
WO2019060660A1 (en) * 2017-09-25 2019-03-28 Merck Sharp & Dohme Corp. CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS

Also Published As

Publication number Publication date
WO2023006923A1 (en) 2023-02-02
CA3226846A1 (en) 2023-02-02
EP4376871A1 (en) 2024-06-05
AU2022320922A1 (en) 2024-01-18
JP2024529452A (ja) 2024-08-06
KR20240043778A (ko) 2024-04-03
CL2024000222A1 (es) 2024-08-02
US20250262279A1 (en) 2025-08-21
CN117677395A (zh) 2024-03-08

Similar Documents

Publication Publication Date Title
MX2024001276A (es) Esquema de dosificacion de agonistas de los receptores de glp1/glucagon de accion prolongada.
ZA202212500B (en) Method of using a gip/glp1 co-agonist for diabetes
CL2020002033A1 (es) Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip. (divisional solicitud 201801795)
Lapierre et al. Treatment of major affective disorder with fluvoxamine.
EP4279135A3 (en) Use of a vegf antagonist to treat diabetic retinopathy
TW200500098A (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
ES2131533T3 (es) Compuestos ciclicos utiles como inhibidores del complejo glicoproteico plaquetario iib/iiia.
CR20210607A (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
WO2021081193A8 (en) Methods of administration of il-2 receptor agonists
WO2024167961A3 (en) Prodrugs of thyroid hormone analogs, methods of making and methods of using thereof
MX2023003758A (es) Formulaciones farmaceuticas.
EA201892778A1 (ru) Фармацевтическая композиция для перорального введения с улучшенной однородностью состава, содержащая пеллеты с замедленным высвобождением, содержащие тамсулозина гидрохлорид
Pironi et al. Evaluation of oral administration of folic and folinic acid to prevent folate deficiency in patients with inflammatory bowel disease treated with salicylazosulfapyridine.
Haubitz et al. Reduced gonadal toxicity after iv cyclophosphamide administration in patients with nonmalignant diseases.
MX2024006130A (es) Nueva composicion farmaceutica que comprende compuestos farmacologicos biofarmaceuticos.
DOP2025000094A (es) Nuevos derivados pirazina-carboxamida sustituidos
WO2022045857A3 (ko) 안정한 약제학적 제제
Shiroky et al. High dose intravenous methotrexate for refractory rheumatoid arthritis.
MX2025004084A (es) Uso de dosis mas altas de formulaciones de huperzina de liberacion modificada
MX2022012847A (es) Composicion para la prevencion o el tratamiento de hiperlipidemia que comprende un agonista trigonal del receptor de glucagon/glp-1/gip o un conjugado del mismo y un procedimiento de uso de la misma.
Vickery et al. Inability of continuous long-term administration of D-Nal (2) 6-LHRH to abolish fertility in male rats.
PH12021553215A1 (en) Pharmaceutical compositions for glucagon and glp-1 co-agonist peptides
MX2024010487A (es) Esquema de administración
Auclair et al. Decrease of the hypertensive responses to phenylephrine in the rat submitted to a sublethal dose of E. coli endotoxin. Restoration by indomethacin (author's transl)
FG et al. Efficacy of individualized phenytoin sodium loading doses administered by intravenous infusion.